Videos

A focused discussion on various risk factors for developing chronic GVHD and steroid-refractory disease.

Yi-Bin Chen, MD, discusses the work-up, diagnosis, and treatment of a 42-year-old woman with moderate steroid-refractory chronic graft-versus-host disease (GVHD).

Michael Chuong, MD, discusses the unmet needs for the treatment of inoperable pancreatic cancer.

John Marshall, MD, discusses the DESTINY-Gastric01 study of fam-trastuzumab deruxtecan-nxki in patients with locally advanced or metastatic HER2-positive gastric cancer.

Afshin Dowlati, MD, discusses treatment decision-making for patients with late-stage small cell lung cancer.

Michael Wang, MD, discusses the study design of the ongoing, multicenter, open-label study examining an acalabrutinib triplet in MCL.

Theodore W. Laetsch, MD, discusses various trials examining larotrectinib in patients with TRK fusion positive thyroid cancer.

Bhavana Pothuri, MD, discusses ongoing and potential studies of copy-number low and high subgroups of patients with endometrial cancer.

Annelise Wilhite, MD, explains what current treatment options look like for patients with vulvar/vaginal melanoma.

Afshin Dowlati, MD, discusses the targeted therapies available for patients with EGFR-mutated late-stage non–small cell lung cancer.

Solange Peters, MD, PhD, discusses the ways in which oncologists can manage toxicities in patients with unresectable malignant pleural mesothelioma.

Richard D. Carvajal, MD, discusses the mechanism of action and efficacy of tebentafusp-tebn for patients with uveal melanoma.

Discussing future needs and investigating novel therapies for newly diagnosed metastatic renal cell carcinoma.

An overview of data demonstrated by other investigational studies of lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma.

Implications for treating patients with metastatic renal cell carcinoma with frontline lenvatinib plus pembrolizumab based on the regimen’s performance in the CLEAR study compared with other treatment options.

Dr Moshe Ornstein examines dosing considerations for the combination of lenvatinib plus pembrolizumab in clinical practice and how that compares with the findings from the CLEAR study.

Ming Zhao, MD, explains the background of the FOHAIC-1 study.

Results of the efficacy and safety data demonstrated by the CLEAR study of lenvatinib plus pembrolizumab or everolimus as first-line treatment for metastatic renal cell carcinoma.

A summary of frontline treatment options for metastatic renal cell carcinoma and the rationale for the combination of lenvatinib plus pembrolizumab.

Closing out her discussion on ovarian cancer, Leslie Randall, MD, shares closing advice for community physicians on optimal treatment strategies.

Leslie Randall, MD, considers the possibility of relapse in ovarian cancer and reviews treatment options available at recurrence.

Ajay Chari, MD, discusses new blood testing options for patients with multiple myeloma.

Focused discussion on the safety profiles of PARP inhibitors in ovarian cancer and how these can be mitigated with proper dose management.

Shared insight on the selection of PARP inhibitors for maintenance therapy in ovarian cancer with deference to patient and disease factors.

A broad look at maintenance therapy selection and its use in ovarian cancer to improve patient outcomes.

Expert Leslie Randall, MD, discusses the case of a 71-year-old woman who is diagnosed with ovarian cancer. Dr. Randall reviews data with PARP inhibitors and rationale for use of maintenance therapy in patients with platinum-sensitive disease.

Daniel P. Petrylak, MD, discusses the targeted therapies that have shown encouraging results in patients with metastatic urothelial cancer.

Ryan Sugarman, MD, discusses the design and purpose of the CheckMate 649 trial for gastroesophageal cancers, gastric cancer, and esophageal adenocarcinoma.

Sophia Kamran, MD, discusses the research supporting the use of trimodality therapy for patients with urothelial cancer.

Nitin Jain, MD, discusses the significance of a study of UCART22, an allogeneic chimeric antigen receptor T-cell therapy for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.